Pharmaceutical companies are successful and influential. Legal actions seeking compensation for damages brought on by harmful drugs are complicated. Bringing a lawsuit might help prospective patients.
An outcome of lawsuits brought against harmful medication producers is more thorough testing. Due to improved safety testing, future patients may be less likely to suffer damage from medicinal drugs. Lawsuits frequently lead to the adoption of new rules intended to safeguard consumers.
Did you receive a retinal vasculitis or retinal vascular occlusion diagnosis after undergoing Beovu treatment for macular degeneration?
What is Beovu Injection?
A biological medication called Beovu injection is used to treat two persistent eye diseases. One of these is neovascular wet age-related macular degeneration (AMD), a significant factor in visual loss in adults over 50. The other one is diabetic macular edema (DME). It is another major factor in eyesight loss and a consequence of diabetes.
What is Beovu used for? Beovu is an injection-only drug produced by Swiss pharmaceutical manufacturer Novartis. The FDA authorized Beovu (brolucizumab dbll – Beovu generic name) on October 7, 2019. Just nine months after the FDA approval, Beovu injections induced an uncommon and severe inflammatory illness in specific patients’ eyes.
Several former Beovu users have filed Beovu lawsuits against the drug’s manufacturer over the past two years. The Beovu lawsuits claimed that the company failed to investigate the adverse effects of the injection marketed to treat AMD and withheld information from users and the medical community about the possibility that Beovu could cause long-term eye damage.
Can Adderall cause retinal detachment? yes, Some people experienced retinal detachment after taking Adderall. It also can cause blurred vision and vision problems.
What Injuries Are Connected to Beovu?
Serious Beovu side effects may cause rapid vision changes or may take several days to manifest. These significant visual changes can sometimes be painful, but they can sometimes be painless. The following are the most common beovu injection side effects:
- Blurred vision
- Difficulty Distinguishing Colors
- Vitreous floaters
- Eye pain
- Conjunctival hemorrhage
- Inflammation of the retinal blood vessels
- Increased eye pressure
- a possible danger of heart attack, stroke, or blood clots
- Retinal hemorrhage
- Vitreous detachment
Beovu does have adverse effects, just like any other drug. Blurred vision was the most frequent adverse response in two Beovu clinical studies, occurring in 10% of participants.
Although the company states that unpleasant side effects happen in less than 10% of people, these side effects have alarmed both patients and medical professionals. Because the injection can cause vision loss and eventually complete blindness, conditions such as retinal vasculitis, retinal vein blockage, retinal detachment, and other symptoms have been identified as particularly concerning.
Aiming to push Beovu into diabetic macular edema, Novartis hopes longer dosing interval can fix eye drug’s safety woes! Expectations for drug crashed after it raised vision-threatening side effects! $NVS #pharma #EyeDisease https://t.co/rQ4LhloTcL
— Helix BioPharma (@HelixBioPharma) August 18, 2021
You must talk to your doctor if you believe you are experiencing any adverse effects from a drug, mainly if they affect your eyes, even though many side effects are minor and transient.
Legal Claims Regarding Potential Risks
The American Society of Retina Specialists (ASRS) warned its members about the connection between Beovu and eye inflammation in February 2020.
Five months after the drug was licensed, the American Society of Retinal Specialists undertook a safety study to see if receiving these injections increased the risk of developing occlusive retinal vasculitis’ potentially harmful side effects.
Their studies revealed 11 diagnoses of occlusive retinal vasculitis in individuals getting Beovu which led to 14 cases of eye injuries. Beovu’s safety has become tricky due to the studies that have linked the product to noticeably higher chances of severe eyesight loss.
The FDA released updated Beovu warning label information on June 11, 2020, emphasizing the possibility of retinal vasculitis and retinal vascular occlusion after the injection. Doctors were instructed to advise patients to notify Beovu immediately if their eyesight changes.
A Nebraska woman allegedly complained to the pharmaceutical beovu manufacturer Novartis that Beovu treatments for macular degeneration caused her to have eye issues. The plaintiff claims that because her doctor believed Beovu to be a safe and effective treatment for her wet AMD, she was given a prescription for it.
She experienced severe eye problems as a result of her Beovu injection, such as central retinal artery occlusion, a blood flow obstruction to the retina of the eye that can result in a rapid loss of vision. Her lawsuit asks for a variety of damages, including general damages, special damages, punitive damages, exemplary damages, and court expenses.
Beovu lawsuits allege that the drug’s maker neglected to inform patients and medical professionals about possible harmful eye effects. A case for damages may be filed by those who used Beovu and had vision loss, retinal vasculitis, occlusive retinal vasculitis, or other visual issues.
Beovu Drug Label Safety Review by Novartis
Following receipt of the ASRS reports of vasculitis and concurrent occlusion, Novartis declared that they would conduct a detailed investigation into the reported cases, commissioning both an external safety review of Beovu and internal research into the side effects reported by the ASRS. 3.3% of the study participants suffered from retinal vasculitis, and 2.1% additionally had vascular occlusion, according to the external safety review.
The pharmaceutical company declared that “there is a confirmed safety signal of rare risk factors of retinal vasculitis and retinal vascular occlusion that may lead to severe vision damage.” The company then submitted an application to the FDA for permission to add warnings about these potential side effects to the product’s packaging.
On June 9, 2020, the FDA approved Novartis’s revision of Beovu’s product labeling, adding a new warning concerning the dangers of retinal vasculitis and retinal vascular occlusion. Before June 2020, when the FDA issued additional warnings concerning blindness and visual loss, more than 50,000 patients had gotten Beovu injections.
Has Beovu Ever Been Recalled?
No. Beovu recall has not been issued; however, in 2020, the FDA authorized label changes involving adverse eye concerns to better notify consumers and medical professionals.
A Novartis safety study conducted in 2020 showed predisposing variables for Beovu eye issues, such as past intraocular inflammation or retinal vascular blockage, within 12 months of the initial injection treatment.
Even though the risk rate for Beovu eye issues was 0.46% for all patients, those who had the mentioned diseases before treatment had a 3.97% risk rate for Beovu complications. Novartis modified Beovu’s safety profile and contraindications to reflect these hazards.
Due to the discovery of Beovu’s connection to ocular inflammation and other issues, Novartis abruptly terminated two more safety trials in May 2021 after disclosing one year’s worth of findings from a Phase III study.
The trials examined the safety and effectiveness of more frequent dosages for Beovu patients. Although the FDA has not yet declared a Beovu recall, the revised label revisions adequately inform patients and physicians of the drug’s hazards.
Beovu September 2022 Update
A federal court in Arkansas rejected an attempt by Novartis to have a Beovu vision injury claim dismissed based on federal preemption. Federal preemption usually causes product liability claims based on a failure to warn to be rejected.
After the judge denied Novartis’ motion to dismiss, the Beovu lawsuits regarding the eye injury were given the green light to proceed.
There is no central MDL, and coordinated pretrial procedures have not been formally created, even though common facts and legal difficulties have been raised in Beovu litigation against Novartis throughout the federal court system. As a result, Beovu lawsuits are ongoing before numerous federal courts in multiple U.S. District Courts around the country.
As cases progress and Beovu trials are planned, they will be closely observed by the Beovu attorneys engaged in the action. They might affect any ultimate Beovu settlement agreements that may be negotiated to prevent each claim from being considered by a jury in the ensuing years.
Value of the Beovu Vision Loss Lawsuit Settlement
Beovu lawsuits for blindness and visual loss are just beginning to be brought against Novartis. Therefore, it is undoubtedly premature to extrapolate the possible Beovu lawsuit settlement value of the Beovu visual loss lawsuit by comparing it to payouts in previous cases involving identical injuries if this action is successful.
In the Beovu lawsuits, each plaintiff will ask for compensation for some degree of eyesight loss or damage. Some will claim to be completely blind, while others will claim to have partial vision loss.
The amount of past and future medical expenditures, whether the plaintiff had an income loss or a loss of earning ability, and the degree of the plaintiff’s pain and suffering all play a role in how much Beovu lawsuits are valued. For instance, someone blind would probably be given more considerable vision loss compensation for their pain and suffering than someone who only lost half of their vision.
Reasons to Bring Beovu Lawsuits
A spate of Beovu lawsuits against Novartis is anticipated following these events. Anyone who took Beovu injections and later suffered from visual problems, blindness, or other adverse effects may be able to sue Novartis. Possible Beovu-related injuries and responses include
- Retinal vasculitis
- Retinal vascular occlusion
- Inflammation of the retina
- Vision loss
After getting injections of the Beovu medication, if you or a loved one had any of the adverse reactions noted above, you may be eligible to file a Beovu vision loss class action lawsuit against Novartis.
More than 70,000 patients used Beovu from its approval in October 2019 to its update warnings in June 2020. All of those patients were unaware of the possible risks and hazards associated with the medicine, as they ought to have been. Patients may be eligible for financial compensation if they trusted the maker and now have damaged eyes.
It’s challenging to bring a Beovu injection lawsuit against a large multinational pharmaceutical business, but knowledgeable Beovu lawyers have the skills and resources to fight for you. Consumers who have been injured by dangerous products, such as Beovu, are protected by product liability lawsuits.
What Are the Forms of Compensation Available to Beovu Victims?
Drug companies may and should be held accountable for how their products impact patients’ health, happiness, and capacity to make a livelihood when they cause harm to patients through unsafe or deficient medications.
Given that Beovu has been connected to lifelong blindness, a disabling condition that has an impact on many facets of life, sufferers may be entitled to substantial Beovu lawsuit settlements, including:
- All costs associated with treating the drug damage, including any ongoing care
- Compensation for lost wages
- Physical and mental anguish brought on by the injury
- Any eyeglasses or other aids you may need to improve your eyesight
- Future earning potential loss or reduction if your eyesight loss prohibits you from working
All these losses are regarded as compensatory damages, which means they’re intended to compensate for the suffering you’ve endured.
A lawsuit must be brought against a pharmaceutical company within certain time limitations. The patient’s bad eye condition was discovered to have been caused by Beovu use at some point. Therefore, that instant serves as a starting point for the time ranges.
Need Medical Record Review ?
The critical pieces of evidence in the Beovu lawsuits will be a complete ophthalmological examination and the patient’s medical history. LezDo techmed can help you in the important process of reviewing your medical records. Every significant medical occurrence that alters the course of a case is highlighted in LezDo techmed’s Medical Narrative Summary Review.
To wrap up,
Beovu is still available despite these warnings about an eye injury. Pharmaceutical firms are responsible for thoroughly evaluating their products and notifying the public of any known harmful effects. Novartis continues to support the medication as a safe and successful therapy for wet AMD. Patients are still in danger, especially if they already have ocular inflammation. Let us know what you think.
Visit our Instagram, to get more insights:
View this post on Instagram